ImmunityBio (IBRX) EBIT (2014 - 2026)
ImmunityBio (IBRX) posted quarterly EBIT of -$69.8 million for Q1 2026, down 8.32% year-over-year from -$76.1 million in Q1 2025, and down 7.9% quarter-over-quarter from -$64.7 million in Q4 2025.
ImmunityBio (IBRX) EBIT (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported EBIT for 13 consecutive years, with -$69.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 8.32% year-over-year to -$69.8 million; the TTM figure through Mar 2026 stood at -$261.4 million (up 16.6% YoY), while the FY2025 annual figure was -$256.0 million, up 25.61% from the prior year.
- EBIT fell to -$69.8 million in Q1 2026 per IBRX's latest filing, from -$64.7 million in the prior quarter.
- Across five years, EBIT topped out at -$55.6 million in Q3 2025 and bottomed at -$111.6 million in Q1 2023.
- Historically, EBIT has averaged -$81.4 million across 5 years, with a median of -$80.3 million in 2024.
- Annual changes were most pronounced in 2024 — EBIT fell 16.66% — and 2025, when it soared 32.32%.
- ImmunityBio's EBIT stood at -$84.9 million in 2022, then slipped by 0.58% to -$85.4 million in 2023, then grew by 18.72% to -$69.4 million in 2024, then increased by 6.8% to -$64.7 million in 2025, then dropped by 7.9% to -$69.8 million in 2026.
- Business Quant data shows IBRX's EBIT at -$69.8 million in Q1 2026, -$64.7 million in Q4 2025, and -$55.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -61.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.70 Mn |
| Mar 31, 2026 | -69.79 Mn |
| Dec 31, 2025 | -64.68 Mn |
| Sep 30, 2025 | -55.63 Mn |
| Jun 30, 2025 | -71.29 Mn |
| Mar 31, 2025 | -64.43 Mn |
| Dec 31, 2024 | -69.40 Mn |
| Sep 30, 2024 | -80.25 Mn |
| Jun 30, 2024 | -99.33 Mn |
| Mar 31, 2024 | -95.20 Mn |
| Dec 31, 2023 | -85.39 Mn |
| Sep 30, 2023 | -80.14 Mn |
| Jun 30, 2023 | -85.15 Mn |
| Mar 31, 2023 | -111.58 Mn |
| Dec 31, 2022 | -84.90 Mn |
| Sep 30, 2022 | -90.80 Mn |
| Jun 30, 2022 | -79.62 Mn |
| Mar 31, 2022 | -95.97 Mn |
| Dec 31, 2021 | -79.27 Mn |
| Sep 30, 2021 | -78.84 Mn |